At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
erlotinib hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD6244 Plus Erlotinib for the Second-Line Treatment of Advanced Pancreatic Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating erlotinib hydrochloride, selumetinib, and 1 other intervention for Adenocarcinoma of the Pancreas and 3 related conditions. Completed, enrolled 46 participants across 2 sites.
Detailed Summary
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy. Selumetinib and erlotinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionApr 2013
Study CompletionSep 2014
TodayJul 2026
First PostedOct 18, 2010
Enrollment StartNov 1, 2010
Primary CompletionApr 1, 2013
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.7 years ago
Interventions
erlotinib hydrochloridedrug
Given PO
selumetinibdrug
Given PO
laboratory biomarker analysisother
Correlative studies